UCB Inspired by patients. Driven by science.

Transcription

1 UCB Inspired by patients. Driven by science. Jean-Christophe Tellier, CEO Full Year 2016 Results Presentation Brussels, 23 February 2017 Carolin, living with epilepsy and axial spondyloarthritis

2 Disclaimer and safe harbor Forward-looking statements 2016 FY results - This presentation contains forward-looking statements, including, without limitation, statements containing the words believes, anticipates, expects, intends, plans, seeks, estimates, may, will, and continue and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation. 2 Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation. UCB expressly disclaims any obligation to update any such forward-looking statements in this presentation to reflect any change in its expectations with regard thereto or any change in events, conditions, for circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.

3 UCB FY 2016 information flow ן Superior and sustainable value for patients, UCB and shareholders 2016 FY results - 3 Jean-Christophe Tellier, CEO ן Strong and sustainable innovation "biotech" model delivering patient value Ismail Kola, CSO ן Continued strong growth in 2016 Detlef Thielgen, CFO ן Conclusion Jean-Christophe Tellier, CEO ן Q&A

4 Environment evolution Patients are waiting for solutions to their health issues 2016 FY results - 4 Technology maturity Empowered patients Cost contained healthcare budgets Increasing demand for value based differentiation

5 Strengthening UCB's Patient Value Strategy 2016 FY results - 5 Innovation will differentiate Networked approach, cross-functional collaboration Engaging stakeholders towards long-term patient value outcomes Top and bottom line growth delivering value

6 UCB's Patient Value Strategy 2016 FY results - 6 Hüseyin, living with RA We deliver highly differentiated solutions to specific populations, striving for a unique experience for each patient. Value for patients => Value for shareholders

7 UCB s strategic growth path True differentiation drives leadership and sustainability 2016 FY results - 7 Strong growth Cimzia, Vimpat, Neupro + Keppra Growth expansion Briviact + Evenity Breakthrough phase Growth expansion by the next wave of products Evenity is the trade name of romosozumab which has been provisionally approved by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA).

8 UCB is progressing on its growth path Priorities - Achievements in FY results - 8 Grow Cimzia, Vimpat and Neupro Combined net sales: million (+20%) Advance and prepare launch of next wave Briviact (brivaracetam) launched Evenity (romosozumab) filed in the U.S., CAN + Japan Strong growth Growth expansion Breakthrough phase Deliver breakthrough solutions Strong pipeline with 10 NMEs 1 Enhance innovation network New collaborations and UCB Ventures Fund Continued focus Value optimizing divestitures established brands: nitrates, venlafaxine ER Deliver 2016 financial outlook "at the upper end of the ranges" 1 NME: New Molecular Entity

9 2016 financial targets achieved Tracking well towards mid-term targets 2016 FY results financial targets vs 2016 achievements Revenue billion 4.2 billion (+8%) rebitda million million (+26%) Core EPS (+47%*) Mid-term financial targets vs 2016 achievements net debt / rebitda ratio 1:1 by :1 two years earlier rebitda / revenue ratio 30% in % in 2016 'CVN' net sales 3.1 billion by billion rebitda: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge * Based on 188 million shares for 2016 and 192 million for 2015

10 10 Strong and sustainable innovation "biotech" model delivering patient value Ismail Kola, CSO

11 "Biotech Characteristics" Scientific excellence connected with deep understanding of patients Super network and open innovation model Innovative breakthrough molecules 2016 FY results - 11 Value Creation Steady flow of breakthrough molecules for own company growth Progress via partnerships innovative assets outside UCB's core focus

12 "Biotech model" - recent partnering examples 2016 FY results - 12 Name Indication Partner Status today vedolizumab moderate to severe colitis ulcerosa Takeda available to patients reslizumab severe asthma and an eosinophilic phenotype Teva available to patients inotuzumab ozogamicin (CMC544) refractory acute lymphoblastic leukemia Pfizer under regulatory review

13 We aim to bring our medicines to specific subpopulations of patients 2016 FY results - 13 Molecular signature / biomarker for stratification seletalisib (PI3K δ) - activated PI3 kinase delta syndrome (APDS) - Phase 1 Histological or imaging identification UCB1332 disease-modification potential for people living with Parkinson s Disease - Phase 1 Clinical presentation & manifestation UCB0942 (PPSI) highly drug resistant epilepsy (patients at least refractory to four AEDs, at least four seizures/week) Phase 2

14 10 new molecules in learn phase development Potential breakthrough to pass decision points 2016 FY results - 14 UCB1332 UCB6673 UCB3491 UCB7858 < - Learn Phase - > bimekizumab add-on to Cimzia RA UCB4144 asthma UCB0942 bimekizumab epilepsy seletalisib various indications UCB7665 dapirolizumab pegol lupus Confirm Phase approval and launch Candidate approval First in human POC* - light in man endpoints for internal decision POC* at Phase 2b robust endpoint Assessment point * POC proof of concept

15 2016 FY results NMEs* in clinical development to deliver breakthrough solutions UCB0942 (PPSI) highly drug resistant epilepsy Strong diverse pipeline with important read-outs in 2017 dapirolizumab pegol (CD40L antibody) systemic lupus erythematosus Phase 2a results: Feb Phase 2b results H (Partner: Biogen) bimekizumab (IL17A/F) Phase 2b results: Q various indications 2 + Q bimekizumab add-on to Cimzia rheumatoid arthritis seletalisib (PI3K δ inhibitor) Sjögren s syndrome + APDS (Phase 1b) UCB7665 immune thrombocytopenia UCB Parkinson s disease UCB4144 / VR942 - asthma UCB immunological diseases UCB epilepsy UCB auto-inflammatory diseases Learn phase POC 1 Phase 1 Phase 2 (Partner: Neuropore) Confirm phase Phase 3 Phase 2a results: H Phase 2a results: end of 2017 Phase 2a results: Q Phase 2a start: 2017 (Partner: Vectura) (Partner: King s College London) Filing neurology immunology * NME: New Molecular Entity 1 POC: Proof of concept 2 bimekizumab: psoriasis (Q3 2017), psoriatic arthritis and ankylosing spondylitis (Q2 2018)

16 Strategic investment in early / disruptive ideas 2016 FY results - 16 "UCB Ventures Fund" to capture external innovation Foster UCB's efforts to identify innovative approaches and/or potential solutions to help improve the lives of patients affected by serious, debilitating diseases. Innovative ideas and projects, Scientific pioneers and entrepreneurs Indirectly (other funds) and directly into newly emerging life sciences/healthcare companies Appropriate opportunities that meet UCB's strategic objectives Investment: 150 million over 3 5 years

17 17 Continued strong growth in 2016 Detlef Thielgen, CFO

18 UCB FY 2016 financial highlights 2016 FY results - 18 Continued delivery on growth strategy top and bottom line Actual CER Revenue Net sales up by 10% (9% CER) to million million +8% +7% Continued net sales growth of core products Total operating expenses Overall operating expense ratio improved to 52% (after 55%) million 2% 3% Recurring EBITDA Margin improved to 25%; rebidta / net debt ratio below 1: million +26% +18% Profit of the Group 520 million attributable to UCB shareholders (-17%) 542 million -20% -27% 2015 benefitted from Kremers Urban divestiture Core earnings per share Based on 188 million weighted average shares outstanding (2015: 192 million shares) % +36%

19 Product mix further improved Cimzia, Vimpat, Neupro = 62% of net sales (2015: 56%) Briviact launched 2016 FY results - 19 FY 2016 net sales* million Cimzia +21% (+21% CER) Strong performance across all regions Vimpat Sustainable growth in all markets Keppra +20% (+20% CER) -2% (-2% CER) Post-exclusivity erosion almost compensated in Japan and international markets Briviact 18 million Launched in EU countries and North America Neupro Growing in all geographies +17% (+18% CER) Established brands -15% (-13% CER) High value divestitures to increase focus and enhance strategic flexibility CER = constant currency exchange rates * Excluding 19 million hedging

20 Top line growth leads to improved ratios* Gross margin ratio 69% 69% 70% Sustainable growth and margin improvement 71% 60% Total operating expense ratio 57% 55% 52% 17% 18% 21% 25% 2016 FY results % FY 2013 FY 2014 FY 2015 FY 2016 FY 2013 FY 2014 FY 2015 FY 2016 FY 2013 FY 2014 FY2015 FY e rebitda ratio tracking towards 30% target * versus revenue

21 Strong Cash Flow "Net debt/rebitda ratio of 1:1" achieved ahead of time 2016 FY results - 21 KU divestiture nitrates, venlafaxine divestiture x Net Cash Flow from continuing operations in million Net Debt & rebitda ratio CAGR: composite annual growth rate

22 Debt maturity schedule 31 December 2016) Perpetual bond called in March 2016 Institutional bond matured in December FY results - 22 ( million) 763 Liquid assets beyond 176 Belgian retail bond Institutional eurobond Other loans EIB loan 176

23 2017 financial outlook 2017e net sales impacted by IFRS 15 and 2016 divestitures 2016 FY results financial targets Revenue billion Continued strong growth: Cimzia, Vimpat, Neupro, Briviact No nitrates, venlafaxine ER sales after divestitures in 2016 Implementation of IFRS 15 Guidance beyond 2017 Mid-term financial targets confirmed "Net debt / rebitda ratio 1:1 by 2018" rebitda / revenue ratio 30% in 2018 rebitda billion R&D expense ratio of ~24% (+/-1% point) Core EPS* Expected underlying tax ratio in the "mid to high twenties" rebitda: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge * ~188 million shares weighted average outstanding

24 Peak sales projections of growth drivers 2016 FY results - 24 First peak sales guidance for Briviact Peak sales by 2020 Peak sales by billion 450 million 1.2 billion 400 million 'CVN' combined 3.1 billion First peak sales guidance for Briviact

25 UCB s value proposition: The patient preferred biopharma Ready to take advantage of a changing environment 2016 FY results - 25 Patient value Shareholder value

26 2016 FY results - 26 Your Questions, please UCB's strategic growth path True differentiation drives leadership and sustainability Strong growth Cimzia, Vimpat, Neupro + Keppra Growth expansion Briviact + Evenity Breakthrough phase - Growth expansion by the next wave of products

27 Further facts and figures 27

28 Recurring EBITDA Solid growth - Improved operating expenses ratio FY 2016 FY 2015 Variance million Actual Actual CER Revenue % 7% Net sales % 9% Royalty income and fees % -24% Other revenue % 5% Gross profit % 8% Marketing and selling expenses % 5% R&D expenses % 0% General and admin expenses % -3% Other operating expense / income > 100% > 100% Total operating expenses % 3% Recurring EBIT % 27% Amortization of intangible assets % 1% Depreciation charges % -9% Recurring EBITDA % 18% 2016 FY results - 28 CER: constant exchange rate EBIT: Earnings before interest and taxes EBITDA: Earning before interests, taxes, depreciation and amortization charges

29 2016 Profit 2016 FY results - 29 FY 2016 FY 2015 Variance million Actual Actual CER Recurring EBIT % 27% Impairment charges % -85% Restructuring expenses % 25% Gain on disposals % 23% Other non-recurring income % -65% Total non-recurring income / expenses (-) > 100% > 100% EBIT % 55% Net financial expenses % 17% Income tax expenses (-) / credit > 100% > 100% Profit from continuing operations % 63% Profit / loss (-) from discontinued operations > -100% > -100% Profit of the Group % -27% Attributable to UCB shareholders % -25% Attributable to non-controlling interests % -56% CER: constant exchange rate EBIT: Earnings before interest and taxes

30 Core earnings per share 2016 FY results - 30 Strong growth of core net profit and less shares outstanding

31 2016 revenue and key product net sales performance 2016 FY results - 31 FY 2016 FY 2015 Variance million Actual Actual CER Revenue % 7% Net sales % 9% Immunology / Cimzia % 21% Neurology % 11% Vimpat % 20% Keppra % -2% Briviact 18 Neupro % 18% Numbers may not add due to rounding CER: constant exchange rate

32 Strong Cimzia performance across all regions 2016 FY results - 32 Cimzia Crohn s disease rheumatoid arthritis psoriatic arthritis axial spondyloarthritis / ankylosing spondylitis 2024 patent expiry (U.S. & EU) Astellas (Japan ) Dermira (psoriasis ) million 2016 net sales 1.5 billion peak sales by 2020 Net sales million FY 2016 FY 2015 Actual CER 1 U.S % 17% Europe % 21% Japan > 100% > 100% International markets % 36% Total Cimzia % 21% EXXELERATE Phase 4 results (Mar 2016) CRADLE Phase 4 results (Mar 2016) juvenile IA³ Phase 3 results (U.S. Mar 2016) RA 4 Phase 3 results (China Aug 2016) juvenile IA³ filing (U.S. Aug 2016) AutoClick prefilled pen - approval (EU) R&D milestones psoriasis Phase 3 results (Jan 2017) CRIB Phase 4 results (Jan 2017) nr axspa² Phase 3 results (U.S ) Numbers may not add due to rounding 3 IA: idiopathic arthritis 1 CER: constant exchange rates 4 RA: rheumatoid arthritis 2 nr axspa: non-radiographic axial spondyloarthritis

33 Strong neurology portfolio performance Leading epilepsy company: The right product for the right patient at the right time 2016 FY results - 33 million FY 2016 FY 2015 Actual CER Vimpat % 20% Keppra % -2% Briviact 18 Total epilepsy % 10% Neupro % 18% Total Neurology % 11% Numbers may not add due to rounding CER: constant exchange rates

34 Vimpat robust growth in all markets, launch in Japan 2016 FY results - 34 Vimpat epilepsy POS patent expiry (U.S. & EU) Daiichi Sankyo (Japan ) 814 million 2016 net sales > 1.2 billion peak sales by 2020 Net sales million FY 2016 FY 2015 Actual CER 1 U.S % 20% Europe % 17% Japan 5 n.a. n.a. International markets % 20% Total Vimpat % 20% epilepsy POS 1 adj. therapy approval (Japan Jul 2016) epilepsy POS 1 adj. therapy filing (China Jul 2016) epilepsy POS 1 ped. adj. therapy filing (EU Aug 2016) epilepsy POS 1 monotherapy filing (Japan Aug 2016) R&D milestones epilepsy POS 1 monotherapy approval (EU Dec 2016) epilepsy POS 1 ped. adj. therapy filing (U.S. Jan 2017) Numbers may not add due to rounding CER: constant exchange rate 1 Partial-onset seizures, also known as focal seizures 2 Primary Generalized Tonic-Clonic Seizures

35 Keppra performance 2016 FY results - 35 Continued in-market demand Keppra epilepsy POS 1 epilepsy PGTCS² epilepsy myoclonic seizures Status of exclusivity: Japan (until 2018) U.S.³ (Nov. 2008) Europe (Sep ) Otsuka (Japan ) 724 million 2016 net sales 1.2 billion peak sales (2008) Net sales million FY 2016 FY 2015 Actual CER U.S % -15% Europe % -2% Japan % 17% International markets % 12% Total Keppra % -2% R&D milestones epilepsy PGTCS 2 adj. therapy - approval (Japan Feb 2016) Numbers may not add due to rounding CER: constant exchange rate 1 Partial-onset seizures, aslo known as focal seizures 2 Primary Generalized Tonic-Clonic Seizures 3 Keppra XR expired in Sep. 2011

36 Briviact launch 2016 FY results - 36 New treatment option for patients living with epilepsy Briviact epilepsy POS patent expiry (U.S. & EU) 18 million 2016 net sales > 450 million peak sales by 2026 Available to patients in: Some EU countries North America Net sales million FY 2016 FY 2015 Actual CER U.S. 11 n.a. n.a. Europe 7 n.a. n.a. International markets 0 n.a. n.a. Total Briviact 18 n.a. n.a. epilepsy POS 1 adj. therapy approval (EU Jan 2016) epilepsy POS 1 adj. therapy approval (U.S. Feb 2016) epilepsy POS 1 adj. therapy approval (Canada Mar 2016) epilepsy POS 1 adj. therapy launch (U.S. Jun 2016) R&D milestones epilepsy POS 1 monotherapy filing (U.S. Jan 2017) Numbers may not add due to rounding CER: constant exchange rate 1 Partial-onset seizures, also known as focal seizures

37 Neupro performance 2016 FY results - 37 Growing in all geographies Neupro Net sales million FY 2016 FY 2015 Actual CER Parkinson s disease restless legs syndrome 2021 patent expiry (U.S. & EU) Otsuka (Japan ) 302 million 2016 net sales 400 million peak sales by 2020 U.S % 5% Europe % 13% Japan >100% >100% International markets % 29% Total Neupro % 18% Numbers may not add due to rounding CER: constant exchange rate

38 Evenity (romosozumab) An innovative investigational bone-building therapy 2016 FY results - 38 Uniquely increases bone formation and decreases bone resorption Opportunity to build bone in high-risk osteoporosis patients, especially post-fracture Under regulatory review in U.S., Canada and Japan STRUCTURE, FRAME and BRIDGE Phase 3 studies completed Manorama, living with osteoporosis ARCH: Phase 3 alendronate-controlled study in postmenopausal women with osteoporosis (primary analysis expected Q2 2017) Evenity is the trade name of romosozumab which has been provisionally approved by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA). Evenity (romosozumab) is developed in partnership with Amgen globally

39 R&D milestones FY results - 39 Vimpat epilepsy POS 1 monotherapy (EU) - filing UCB3491 epilepsy Phase 1 start Briviact epilepsy POS 1 adj. therapy approval (EU) Briviact epilepsy POS 1 adj. therapy approval (U.S.) E Keppra epilepsy PGTCS 2 adj. therapy approval (Japan) Cimzia C-EARLY Phase 4 results romosozumab osteoporosis in postmenopausal women (FRAME) Phase 3 results romosozumab osteoporosis in men (BRIDGE) Phase 3 results Cimzia EXXELERATE Phase 4 results UCB7665 ITP 3 Phase 2a start Cimzia juvenile IA 4 Phase 3 results UCB4144 / VR942 asthma Phase 1 results seletalisib (UCB5857) APDS 5 Phase 1b start dapirolizumab pegol SLE 6 Phase 2b start Vimpat epilepsy POS 1 adj. therapy approval (Japan) romosozumab osteoporosis in postmenopausal women BLA 7 (U.S.) Cimzia juvenile IA 4 filing (U.S.) Vimpat epilepsy POS 1 monotherapy filing (Japan) bimekizumab psoriasis Phase 2b start Vimpat epilepsy POS 1 ped. adj. therapy Filing (EU) Cimzia Auto-injector approval (EU) Cimzia psoriasis Phase 3 results Cimzia women in child bearing age Phase 4 results bimekizumab various indications Phase 2b start 1 POS: Partial-Onset Seizures 5 APDS: Activated PI3 Kinase Delta Syndrome 2 PGTCS: Primary Generalized Tonic-Clonic Seizures 6 SLE: Systemic Lupus Erythematosus 3 ITP: Idiopathic Thrombocytopenia 7 BLA: biologic license application 4 IA: Idiopathic Arthritis neurology immunology bone

40 R&D milestones 2016 FY results - 40 H H > > Cimzia psoriasis Phase 3 results UCB0942 highly drug resistant epilepsy Phase 2a results bimekizumab psoriasis Phase 2b results Cimzia nr axspa (U.S.) Phase 3 results Vimpat epilepsy PGTCS adj. therapy Phase 3 results bimekizumab add on to Cimzia rheumatoid arthritis Phase 2a results Vimpat epilepsy POS ped. adj. therapy Phase 3 results UCB7665 Immune thrombocitopenia Phase 2a results dapirolizumab pegol SLE Phase 2b results romosozumab osteoporosis in post-menopausal women (ARCH) Phase 3 results UCB4144 / VR942 asthma Phase 2a start bimekizumab psoriatic arthritis Phase 2b results neurology seletalisib Sjögren s syndrome Phase 2a results bimekizumab ankylosing spondylitis Phase 2b results immunology bone POS: Partial-Onset Seizures, also known as focal seizures nr axspa: non-radiographic axial spondyloarthritis SLE: Systemic Lupus Erythematosus

41 Cimzia in-market performance FY results - 41 U.S. Europe Japan 5% 3% 1% -1% -3% -5% Cimzia vs. anti-tnf 1 Market Growth -3.3% 0.8% -0.1% Anti TNF Biologics Cimzia +3.2% 20% 15% 10% 5% 0% Cimzia vs. Rheumatology 1 Market Growth 17.0% 5.4% 8.6% Anti TNF Biologics Cimzia +11.6% 20% 15% 10% 5% 0% Cimzia vs. RA Market Growth 7.7% 10.3% 18.3% Anti TNF Biologics Cimzia +10.5% 6.5% 6.0% 5.5% 5.0% Cimzia Rheumatology R3M Patient Share +0.4% 5.5% 9.0% 8.5% 8.0% 7.5% Cimzia Rheumatology 1 R3M Patient Share +0.8% 8.5% 4.5% 4.0% 3.5% 3.0% Cimzia RA R3M Patient Share +0.4% 3.9% 4.5% Nov-15 Feb-16 May-16 Aug-16 Nov-16 Source: U.S: IMS Source of Business Report November % Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source: IMS MIDAS In-Market KPI s are based on Exit Patients 2.5% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source: IMS MIDAS; Cimzia patients are considered 100% in RA In-Market KPI s are based on Exit Patients 1 hares calculated based on Anti-TNF market. In-market growth is calculated for MAT Dec 15 vs. Dec 16 Market share is calculated for Dec 16 and market share growth is shown against R3M Dec 15

42 Vimpat in-market performance FY results - 42 U.S. Europe Japan 20% 15% Vimpat vs. AED Market Growth (TRx) 14.2% 20% 15% Vimpat vs. AED Market Growth (TDx) 15.1% 20% 15% Vimpat vs. AED Market Growth (TDx) 10% 5% 0% 4.5% AED Market +9.6% Vimpat 10% 5% 0% -5% -0.7% AED Market Vimpat +15.9% 10% 5% 0% 4.1% AED Market Numbers to be populated when sufficient data is available Vimpat 4.5% 4.3% 4.1% 3.9% 3.7% Vimpat R3M TRx Share +0.3% 4.0% 3.5% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source data U.S.: U.S. IMS NPA In-Market KPIs are based on TRx 3.5% 3.3% 3.1% 2.9% 2.7% Vimpat R3M TDx Share +0.4% 3.0% 2.5% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source data EU: IMS MIDAS In-Market KPI s are based on TDx Vimpat R3M TDx Share 0.2% 0.5% 0.4% 0.3% 0.2% 0.1% 0.0% Dec-15 Feb-16 Apr-16 Jun-16 Aug-16 Oct-16 Dec-16 AED = anti epileptic drug - AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage. AED Market and Vimpat growth are calculated for MAT Dec 16 vs. MAT Dec 15. Vimpat market share is calculated for R3M Dec 16 and market share growth is shown against R3M Dec 15

43 Keppra in-market performance FY results % 6.0% 4.0% 2.0% 0.0% -2.0% -4.0% -6.0% -8.0% -10.0% 2.0% 1.5% 1.0% 0.5% 4.5% U.S. Keppra vs. AED Market Growth (TRx) -9.4% AED Market Keppra Keppra R3M TRx Share -0.1% -13.9% 0.9% 0.0% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source data U.S.: U.S. IMS NPA In-market KPI s are based on TRx 8.0% 6.0% 4.0% 2.0% 0.0% -2.0% -4.0% -6.0% -8.0% -10.0% 13.0% 12.5% 12.0% 11.5% Keppra vs. AED Market Growth (TDx) 6.8% -0.7% AED Market Europe Keppra R3M TDx Share +0.8% Keppra 12.4% 11.0% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source data EU, JP: IMS MIDAS In-market KPI s are based on TDx +7.6% 50% 40% 30% 20% 10% 0% 14.0% 12.0% 10.0% Keppra vs. AED Market Growth (TDx) 42.5% 4.1% Japan AED Market Keppra Keppra R3M TDx Share +3.8% +38.5% 13.6% 8.0% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source data EU, JP: IMS MIDAS In-market KPI s are based on TDx AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage. For U.S, Keppra includes Keppra XR. For EU, Keppra does not include UCB Levetiracetam. AED Market and Keppra TRx growth are calculated for MAT Dec 16 vs. MAT Dec 15. Keppra TRx market share is calculated for R3M Dec 16 and market share growth is shown against R3M Dec 15

44 Neupro in-market performance FY results - 44 U.S. Europe Japan 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% -2.0% Neupro PD vs. PD (KC) Market Growth (TRx) 0.9% 0.9% PD Market PD Key Competitors -0.4% Neupro -1.3% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% -2.0% Neupro PD vs. PD (KC) Market Growth (TDx) 2.6% PD Market 0.5% PD Key Competitors 8.4% Neupro +7.9% 30% 25% 20% 15% 10% 5% 0% Neupro PD vs. PD (KC) Market Growth (TDx) 0.7% PD Market 2.1% PD Key Competitors 24.6% Neupro +22.5% 8.0% 7.0% Neupro PD R3M TRx Share -0.3% 6.7% 6.0% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source data U.S.: U.S. IMS NPA In-market KPI s are based on TRx 18.5% 18.0% 17.5% 17.0% 16.5% Neupro PD R3M TDx Share +1.2% 17.9% 16.0% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source data EU, JP: IMS MIDAS In-market KPI s are based on TDx 28% 26% 24% 22% Neupro PD R3M TDx Share +3.6% 26.3% 20% Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Source data EU, JP: IMS MIDAS In-market KPI s are based on TDx PD market: All molecules in ATC3= N4A. In the EU and Japan, the TDx of all these molecules are factored for PD usage. In the US, only the TRx of Rotigotine, Pramipexole and Ropinirole are factored for PD usage. PD Key Competitors (KC) market: The 8 DA s (Dopamine Antagonists): Bromocriptine, Cabergoline, Lisuride, Pergolide, Rotigotine, Pramipexole, Piribedil, Ropinirole. In the US, only Rotigotine, Pramipexole and Ropinirole are factored for PD usage, hence the PD market and PD KC market are the same.

45 Briviact in-market performance 2016 A new therapeutic option in the AED market 2016 FY results - 45 U.S. Europe Briviact R3M TRx Share 0.08% 0.10% 0.08% 0.06% 0.04% 0.02% 0.00% Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Briviact R3M TDx Share 0.29% 0.35% 0.30% 0.25% 0.20% 0.15% 0.10% 0.05% 0.00% Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Source data U.S.: U.S. IMS NPA In-Market KPIs are based on TRx Source data EU: IMS MIDAS In-Market KPI s are based on TDx AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage. Briviact TDx/TRx market share is calculated on R3M Dec 16

46 One UCB today: A Global Player Presence in 38 countries completed by a robust network of partners 2016 FY results RESEARCH CENTERS Braine-l Alleud (Belgium) Slough (U.K.) 5 DEVELOPMENT HUBS RTP North Carolina (U.S.) Monheim (Germany) Brussels (Belgium) Tokyo (Japan) 4 Shanghai (China) MANUFACTURING FACILITIES Braine-l Alleud (Belgium) Zuhai (China) Saitama (Japan) Bulle (Switzerland) employees globally December 2016

47 Shareholder structure Stable shareholder base with free-float of 61% Total number of shares: million Weighted average shares outstanding in 2016: 188 million 2016 FY results - 47 Free float investors by region Source: Notifications and UCB underlying ownership analysis

48 Your UCB Investor Relations team 2016 FY results - 48 ן Antje Witte, Vice President Investor Relations Phone: antje.witte@ucb.com ן Isabelle Ghellynck, Director Investor Relations Phone: isabelle.ghellynck@ucb.com ן Nathalie Deldime, Investor Relations Manager Phone: nathalie.deldime@ucb.com ן Check out our new IR App stay tuned wherever you go